Double-Detargeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability

Background We have previously developed an oncolytic serotype 5 adenovirus (Ad5) with chromogranin-A (CgA) promoter-controlled E1A expression, Ad[CgA-E1A], with the intention to treat neuroendocrine tumors, including carcinoids. Since carcinoids tend to metastasize to the liver it is important to fully repress viral replication in hepatocytes to avoid adenovirus-related liver toxicity. Herein, we explore miRNA-based regulation of E1A expression as a complementary mechanism to promoter-based transcriptional control. Methodology/Principal Findings Ad[CgA-E1A-miR122], where E1A expression is further controlled by six tandem repeats of the target sequence for the liver-specific miR122, was constructed and compared to Ad[CgA-E1A]. We observed E1A suppression and replication arrest of the miR122-detargeted adenovirus in normal hepatocytes, while the two viruses killed carcinoid cells to the same degree. Repeated intravenous injections of Ad[CgA-E1A] induced liver toxicity in mice while Ad[CgA-E1A-miR122] injections did not. Furthermore, a miR122-detargeted adenovirus with the wild-type E1A promoter showed reduced replication in hepatic cells compared to wild-type Ad5 but not to the same extent as the miR122-detargeted adenovirus with the neuroendocrine-selective CgA promoter. Conclusions/Significance A combination of transcriptional (promoter) and post-transcriptional (miRNA target) regulation to control virus replication may allow for the use of higher doses of adenovirus for efficient tumors treatment without liver toxicity.

[1]  K. Yagi,et al.  miR-122a-Regulated Expression of a Suicide Gene Prevents Hepatotoxicity Without Altering Antitumor Effects in Suicide Gene Therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  E. Seregni,et al.  Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors , 1999, Cancer.

[3]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[4]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[5]  M. Essand,et al.  A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy , 2007, Clinical Cancer Research.

[6]  A. Danielsson,et al.  Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region , 2008, Cancer Gene Therapy.

[7]  A. Munnich,et al.  miR-122, a paradigm for the role of microRNAs in the liver. , 2008, Journal of hepatology.

[8]  U. Pettersson,et al.  Structural proteins of adenoviruses. IV. Sequential degradation of the adenovirus type 2 virion. , 1970, Virology.

[9]  L. Naldini,et al.  Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer , 2006, Nature Medicine.

[10]  N. Van Rooijen,et al.  Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells , 2009, PLoS pathogens.

[11]  M. Hitt,et al.  Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. , 1990, Virology.

[12]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature reviews genetics.

[13]  Luigi Naldini,et al.  Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state , 2007, Nature Biotechnology.

[14]  L. Eiden,et al.  The chromogranins: Their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia , 2003, Endocrine pathology.

[15]  U. Pettersson,et al.  Structural proteins of adenoviruses , 1971 .

[16]  R. Andino,et al.  Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA , 2008, Journal of Virology.

[17]  M. Barry,et al.  Current advances and future challenges in Adenoviral vector biology and targeting. , 2007, Current gene therapy.

[18]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[19]  K. Yagi,et al.  miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  M. Essand,et al.  Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1. , 2005, Journal of molecular endocrinology.

[21]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[22]  M. Essand,et al.  A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  S. Russell,et al.  Engineering microRNA responsiveness to decrease virus pathogenicity , 2008, Nature Medicine.

[24]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[25]  K. Helle,et al.  The endocrine role for chromogranin A: A prohormone for peptides with regulatory properties , 2007, Cellular and Molecular Life Sciences.